Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Neuropharmacology
  4. Volume 23, Issue 7
  5. Article
Volume 23, Issue 7
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

Objective

Limited research has delved into the comprehensive impact of monotherapy on weight and glycolipid metabolism in schizophrenia (SCZ) patients. Our study aims to longitudinally investigate the multidimensional effects of olanzapine (OLA) monotherapy on weight and glycolipid metabolism in first-episode and antipsychotic-naïve (FEAN) SCZ patients.

Methods

A total of 74 FEAN-SCZ patients were recruited, as well as 58 sex- and age-matched healthy controls. Eligible patients underwent a 4-week OLA treatment regimen, with weight assessments conducted at baseline and week 4. Moreover, lipid profiles and fasting plasma glucose (FPG) were measured at baseline and week 4. Insulin, leptin (LEP), and adiponectin (APN) levels were determined using enzyme-linked immunosorbent assay (ELISA) kits.

Results

At baseline, FEAN-SCZ patients showed elevated levels of insulin, low-density lipoprotein (LDL), impaired insulin sensitivity, and reduced levels of APN compared to the healthy controls. Following 4-week OLA treatment, patients showed an increase in body mass index (BMI) of 0.96 kg/m2. Additionally, FPG, quantitative insulin sensitivity check index (QUICKI), HOMA-insulin sensitivity index (HOMA-ISI), and fasting plasma glucose to insulin ratio (G/I) displayed significant decreases, while insulin, HOMA-IR, and LEP levels showed significant increases. Stepwise regression analysis revealed that baseline FPG independently predicted the change in BMI after 4 weeks of OLA treatment.

Conclusion

FEAN-SCZ patients exhibited pre-existing alterations in glucose homeostasis. After 4 weeks of OLA treatment, SCZ patients experienced significant weight gain, deteriorating insulin resistance, and increased LEP levels. In addition, baseline FPG emerged as a predictor of BMI changes after 4 weeks of OLA treatment.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/1570159X23666240918103730
2024-09-20
2025-05-18

  • From This Site

    /content/journals/cn/10.2174/1570159X23666240918103730
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. AliS. SantomauroD. FerrariA.J. CharlsonF. Schizophrenia as a risk factor for cardiovascular and metabolic health outcomes: A comparative risk assessment.Epidemiol. Psychiatr. Sci.202332e810.1017/S2045796023000045 36756905
     [Google Scholar]
  2. PillingerT. McCutcheonR.A. VanoL. MizunoY. ArumuhamA. HindleyG. BeckK. NatesanS. EfthimiouO. CiprianiA. HowesO.D. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis.Lancet Psychiatry202071647710.1016/S2215‑0366(19)30416‑X 31860457
     [Google Scholar]
  3. TandonR. NasrallahH.A. KeshavanM.S. Schizophrenia, “Just the Facts” 5. treatment and prevention past, present, and future.Schizophr. Res.20101221-312310.1016/j.schres.2010.05.025 20655178
     [Google Scholar]
  4. BartonB.B. SeggerF. FischerK. ObermeierM. MusilR. Update on weight-gain caused by antipsychotics: A systematic review and meta-analysis.Expert Opin. Drug Saf.202019329531410.1080/14740338.2020.1713091 31952459
     [Google Scholar]
  5. McQuadeR.D. StockE. MarcusR. JodyD. GharbiaN.A. VanveggelS. ArchibaldD. CarsonW.H. A comparison of weight change during treatment with olanzapine or aripiprazole: Results from a randomized, double-blind study.J. Clin. Psychiatry200465184756 15600384
     [Google Scholar]
  6. ZhangW. ClineM.A. GilbertE.R. Hypothalamus-adipose tissue crosstalk: Neuropeptide Y and the regulation of energy metabolism.Nutr. Metab.20141112710.1186/1743‑7075‑11‑27 24959194
     [Google Scholar]
  7. BreitA. WolffK. KalwaH. JarryH. BüchT. GudermannT. The natural inverse agonist agouti-related protein induces arrestin-mediated endocytosis of melanocortin-3 and -4 receptors.J. Biol. Chem.200628149374473745610.1074/jbc.M605982200 17041250
     [Google Scholar]
  8. McEvoyJ.P. LiebermanJ.A. PerkinsD.O. HamerR.M. GuH. LazarusA. SweitzerD. OlexyC. WeidenP. StrakowskiS.D. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison.Am. J. Psychiatry200716471050106010.1176/ajp.2007.164.7.1050 17606657
     [Google Scholar]
  9. MisiakB. FrydeckaD. ŁaczmańskiŁ. ŚlęzakR. KiejnaA. Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.Eur. J. Clin. Pharmacol.201470121433144110.1007/s00228‑014‑1762‑2 25291992
     [Google Scholar]
  10. SikichL. HamerR.M. BashfordR.A. SheitmanB.B. LiebermanJ.A. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial.Neuropsychopharmacology200429113314510.1038/sj.npp.1300327 14583740
     [Google Scholar]
  11. KaushalJ. BhutaniG. GuptaR. Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone.Singapore Med. J.2012537488492 22815019
     [Google Scholar]
  12. SenguptaS. ParrillaescobarM. KlinkR. FathalliF. Yingkinng, StipE. BaptistaT. MallaA. JooberR. Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls?Schizophr. Res.20081021-332933610.1016/j.schres.2008.02.013 18396386
     [Google Scholar]
  13. ArranzB. RoselP. RamírezN. DueñasR. FernándezP. SanchezJ.M. NavarroM.A. SanL. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients.J. Clin. Psychiatry200465101335134210.4088/JCP.v65n1007 15491236
     [Google Scholar]
  14. DasguptaA. SinghO.P. RoutJ.K. SahaT. MandalS. Insulin resistance and metabolic profile in antipsychotic naïve schizophrenia patients.Prog. Neuropsychopharmacol. Biol. Psychiatry20103471202120710.1016/j.pnpbp.2010.06.011 20600470
     [Google Scholar]
  15. WangC. WangC. RenL. ChenS. ChenW.H. LiY. The protein kinase D1-mediated inflammatory pathway is involved in olanzapine-induced impairment of skeletal muscle insulin signaling in rats.Life Sci.202127011903710.1016/j.lfs.2021.119037 33497738
     [Google Scholar]
  16. LiD. YueQ. LiuL. CheK. LiuX. HuC. Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats.Acta Pharmacol. Sin.20214281267127910.1038/s41401‑021‑00680‑x 33976388
     [Google Scholar]
  17. JassimG. SkredeS. VázquezM.J. WergedalH. Vik-MoA.O. LunderN. DiéguezC. Vidal-PuigA. BergeR.K. LópezM. SteenV.M. FernøJ. Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat.Psychopharmacology2012219378379410.1007/s00213‑011‑2397‑y 21748251
     [Google Scholar]
  18. FerreiraV. GrajalesD. ValverdeÁ.M. Adipose tissue as a target for second-generation (atypical) antipsychotics: A molecular view.Biochim. Biophys. Acta Mol. Cell Biol. Lipids20201865215853410.1016/j.bbalip.2019.158534 31672575
     [Google Scholar]
  19. DengY. SchererP.E. Adipokines as novel biomarkers and regulators of the metabolic syndrome.Ann. N. Y. Acad. Sci.201012121E1E1910.1111/j.1749‑6632.2010.05875.x 21276002
     [Google Scholar]
  20. ChenC.Y.A. GohK.K. ChenC.H. LuM.L. The role of adiponectin in the pathogenesis of metabolic disturbances in patients with schizophrenia.Front. Psychiatry20211160512410.3389/fpsyt.2020.605124 33551872
     [Google Scholar]
  21. KimJ.H. KimJ.H. ParkP.W. MachannJ. RodenM. LeeS.W. HwangJ.H. Body and liver fat content and adipokines in schizophrenia: A magnetic resonance imaging and spectroscopy study.Psychopharmacology2017234121923193210.1007/s00213‑017‑4598‑5 28315932
     [Google Scholar]
  22. BartoliF. LaxA. CrocamoC. ClericiM. CarràG. Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: A meta-analysis.Psychoneuroendocrinology20155617918910.1016/j.psyneuen.2015.03.012 25827962
     [Google Scholar]
  23. LiuQ. YuanB. LoK.A. PattersonH.C. SunY. LodishH.F. Adiponectin regulates expression of hepatic genes critical for glucose and lipid metabolism.Proc. Natl. Acad. Sci.201210936145681457310.1073/pnas.1211611109 22904186
     [Google Scholar]
  24. LiS. XuC. TianY. WangX. JiangR. ZhangM. WangL. YangG. GaoY. SongC. HeY. ZhangY. LiJ. LiW.D. TOX and ADIPOQ gene polymorphisms are associated with antipsychotic-induced weight gain in han chinese.Sci. Rep.2017714520310.1038/srep45203 28327672
     [Google Scholar]
  25. LiS. ChenD. XiuM. LiJ. ZhangX.Y. Prevalence and clinical correlates of impaired glucose tolerance in first-episode versus chronic patients with schizophrenia.Early Interv. Psychiatry202216998599310.1111/eip.13240 34743408
     [Google Scholar]
  26. PetruzzelliM.G. MargariM. PeschecheraA. de GiambattistaC. De GiacomoA. MateraE. MargariF. Hyperprolactinemia and insulin resistance in drug naive patients with early onset first episode psychosis.BMC Psych.201818124610.1186/s12888‑018‑1827‑3 30068291
     [Google Scholar]
  27. PetrikisP. TigasS. TzallasA.T. PapadopoulosI. SkapinakisP. MavreasV. Parameters of glucose and lipid metabolism at the fasted state in drug-naïve first-episode patients with psychosis: Evidence for insulin resistance.Psychiatry Res.2015229390190410.1016/j.psychres.2015.07.041 26279127
     [Google Scholar]
  28. ChenS. Broqueres-YouD. YangG. WangZ. LiY. WangN. ZhangX. YangF. TanY. Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia.Psychiatry Res.2013210382582910.1016/j.psychres.2013.08.056 24113122
     [Google Scholar]
  29. WuX. HuangZ. WuR. ZhongZ. WeiQ. WangH. DiaoF. WangJ. ZhengL. ZhaoJ. ZhangJ. The comparison of glycometabolism parameters and lipid profiles between drug-naïve, first-episode schizophrenia patients and healthy controls.Schizophr. Res.2013150115716210.1016/j.schres.2013.07.051 23998954
     [Google Scholar]
  30. KayS.R. FiszbeinA. OplerL.A. The positive and negative syndrome scale (PANSS) for schizophrenia.Schizophr. Bull.198713226127610.1093/schbul/13.2.261 3616518
     [Google Scholar]
  31. WuB.J. LanT.H. HuT.M. LeeS.M. LiouJ.Y. Validation of a five-factor model of a chinese mandarin version of the positive and negative syndrome scale (CMV-PANSS) in a sample of 813 schizophrenia patients.Schizophr. Res.20151691-348949010.1016/j.schres.2015.09.011 26443481
     [Google Scholar]
  32. ZhangX.Y. ChenD.C. TanY.L. AnH.M. Zunta-SoaresG.B. HuangX.F. SoaresJ.C. Glucose disturbances in first-episode drug-naïve schizophrenia: Relationship to psychopathology.Psychoneuroendocrinology20156237638010.1016/j.psyneuen.2015.09.005 26385108
     [Google Scholar]
  33. SteinerJ. BergerM. GuestP.C. DobrowolnyH. WestphalS. SchiltzK. SarnyaiZ. Assessment of insulin resistance among drug-naive patients with first-episode schizophrenia in the context of hormonal stress axis activation.JAMA Psychiatry201774996897010.1001/jamapsychiatry.2017.1983 28724123
     [Google Scholar]
  34. SongX. FanX. SongX. ZhangJ. ZhangW. LiX. GaoJ. HarringtonA. ZiedonisD. LvL. Elevated levels of adiponectin and other cytokines in drug naïve, first episode schizophrenia patients with normal weight.Schizophr. Res.2013150126927310.1016/j.schres.2013.07.044 23968860
     [Google Scholar]
  35. OuJ.J. XuY. ChenH.H. FanX. GaoK. WangJ. GuoX.F. WuR.R. ZhaoJ.P. Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia.Psychopharmacology2013225362763510.1007/s00213‑012‑2850‑6 22926006
     [Google Scholar]
  36. HahnM.K. WoleverT.M.S. ArenovichT. TeoC. GiaccaA. PowellV. ClarkeL. FletcherP. CohnT. McIntyreR.S. GomesS. ChintohA. RemingtonG.J. Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls.J. Clin. Psychopharmacol.201333674074610.1097/JCP.0b013e31829e8333 24100786
     [Google Scholar]
  37. KonarzewskaB. WaszkiewiczN. GalińskaB. SzulcA. Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone.Neuroendocrinol. Lett.2013344322328 23803867
     [Google Scholar]
  38. HuS. YaoM. PetersonB.S. XuD. HuJ. TangJ. FanB. LiaoZ. YuanT. LiY. YueW. WeiN. ZhouW. HuangM. XuY. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.Psychopharmacology2013230131310.1007/s00213‑013‑3073‑1 23559220
     [Google Scholar]
  39. HarrisL.W. GuestP.C. WaylandM.T. UmraniaY. KrishnamurthyD. RahmouneH. BahnS. Schizophrenia: Metabolic aspects of aetiology, diagnosis and future treatment strategies.Psychoneuroendocrinology201338675276610.1016/j.psyneuen.2012.09.009 23084727
     [Google Scholar]
  40. GuestP.C. SchwarzE. KrishnamurthyD. HarrisL.W. LewekeF.M. RothermundtM. van BeverenN.J.M. SpainM. BarnesA. SteinerJ. RahmouneH. BahnS. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia.Psychoneuroendocrinology20113671092109610.1016/j.psyneuen.2010.12.018 21251762
     [Google Scholar]
  41. TaoQ. MiaoY. LiH. YuanX. HuangX. WangY. AndreassenO.A. FanX. YangY. SongX. Insulin resistance and oxidative stress: In relation to cognitive function and psychopathology in drug-naïve, first-episode drug-free schizophrenia.Front. Psychiatry20201153728010.3389/fpsyt.2020.537280 33329081
     [Google Scholar]
  42. PreissD. SattarN. Lipids, lipid modifying agents and cardiovascular risk: A review of the evidence.Clin. Endocrinol.200970681582810.1111/j.1365‑2265.2008.03490.x 19067719
     [Google Scholar]
  43. ColemanR.A. MashekD.G. Mammalian triacylglycerol metabolism: Synthesis, lipolysis, and signaling.Chem. Rev.2011111106359638610.1021/cr100404w 21627334
     [Google Scholar]
  44. GrajalesD. FerreiraV. ValverdeÁ.M. Second-generation antipsychotics and dysregulation of glucose metabolism: Beyond weight gain.Cells2019811133610.3390/cells8111336 31671770
     [Google Scholar]
  45. HanH.S. KangG. KimJ.S. ChoiB.H. KooS.H. Regulation of glucose metabolism from a liver-centric perspective.Exp. Mol. Med.2016483e21810.1038/emm.2015.122 26964834
     [Google Scholar]
  46. KimE. ParkD.W. ChoiS.H. KimJ.J. ChoH.S. A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia.J. Clin. Psychopharmacol.200828213814610.1097/JCP.0b013e31816777f7 18344723
     [Google Scholar]
  47. Sepúlveda-LizcanoL. Arenas-VillamizarV.V. Jaimes-DuarteE.B. García-PachecoH. ParedesC.S. BermúdezV. Rivera-PorrasD. Metabolic adverse effects of psychotropic drug therapy: A systematic review.Eur. J. Investig. Health Psychol. Educ.20231381505152010.3390/ejihpe13080110 37623307
     [Google Scholar]
/content/journals/cn/10.2174/1570159X23666240918103730
Loading
Olanzapine-Induced Weight Gain and Glycolipid Metabolism Aberrations in First-Episode and Antipsychotic-Naïve Schizophrenia Patients: A Longitudinal Study
Curr. Neuropharmacol. 23, 771 (2025); https://doi.org/10.2174/1570159X23666240918103730
/content/journals/cn/10.2174/1570159X23666240918103730
/content/journals/cn/10.2174/1570159X23666240918103730
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): antipsychotic-naïve; first-episode; glycolipid metabolism; insulin; olanzapine; Schizophrenia; weight gain

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test